Stayble Therapeutics AB publishes prospectus relating to the issuance of units in connection with the intended listing on Nasdaq First North Growth Market
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), AUSTRALIA, NEW ZEALAND, JAPAN, CANADA, HONG KONG OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE. Stayble Therapeutics AB (“Stayble” or the “Company”) has composed a prospectus for the issuance of units to institutional investors and the public in Sweden in connection with the intended listing of the Company’s share on Nasdaq First North Growth Market (“Nasdaq First North”). The prospectus, approved and registered with the Swedish Financial Supervisory Authority today January 31, 2020, is available on the Company’s webpage (www.staybletherapeutics.com) and on Mangold Fondkommission’s webpage (www.mangold.se). The prospectus will also be made available on the Swedish Financial Supervisory Authority´s webpage (www.fi.se).
Subscription forms, teaser and other information regarding the issuance of units and the listing of the Company’s share on Nasdaq First North will be made available on the Company’s and Mangold’s webpages on February 4 when the subscription period commence.
Mangold Fondkommission AB are financial advisors and Advokatfirman Schjødt are legal advisors in connection with the Offering.